INTRODUCTION
============

Although combat sport competitions are divided into weight classes, most athletes reduce significant amounts of body weight in the days prior to weigh-in to compete against smaller opponents and thus obtain competitive advantage ([@b3-jer-14-1-83]). Achieving large weight reductions in short periods of time requires a combination of different procedures, including severe food restriction and increased training loads ([@b2-jer-14-1-83]). Among several adverse effects of rapid weight loss, we highlight the immune system depression which is typically accompanied by increased susceptibility to opportunistic infections ([@b15-jer-14-1-83]; [@b18-jer-14-1-83]). Immunosuppression and consequential infections hold potential to impair competitive performance. Anecdotal reports have shown increased frequencies of the common cold, upper respiratory infections, herpes and conjunctivitis in combat athletes during weight loss periods ([@b15-jer-14-1-83]).

Plasma glutamine levels have long been considered crucial for immune function since the glutamine supply for leukocytes relies entirely on plasma availability ([@b1-jer-14-1-83]). In neutrophils and macrophages, glutamine is important for rapid energy provision and for the synthesis of membrane lipids and reducing agents (nicotinamide adenine dinucleotide phosphate and nicotinamide adenine dinucleotide phosphate, both important for the regulation of oxidative burst) ([@b6-jer-14-1-83]). In rats, glutamine supplementation improves neutrophil function ([@b22-jer-14-1-83]; [@b21-jer-14-1-83]). In humans, studies with critical and surgical patients ([@b24-jer-14-1-83]) and healthy exercising volunteers ([@b5-jer-14-1-83]; [@b7-jer-14-1-83]; [@b30-jer-14-1-83]) also provide support for a role of plasma glutamine on immune function. In athletes, [@b17-jer-14-1-83] observed lower plasma glutamine in those with overtraining syndrome in comparison to their counterparts without chronic fatigue; all athletes presenting clinical symptoms of infection also had glutamine levels below 450 mmol/L. In a placebo-controlled trial, [@b5-jer-14-1-83] showed that glutamine supplementation was related to a significant decrease in the incidence of upper respiratory infection symptoms ([@b5-jer-14-1-83]; [@b17-jer-14-1-83]). In judoists, glutamine supplementation improved neutrophil function following a single training session by increasing oxidative burst ([@b30-jer-14-1-83]).

However, the efficacy of glutamine supplementation in athletes remains controversial, as some studies have failed to show positive effects on exercise-related immunosuppression ([@b19-jer-14-1-83], [@b20-jer-14-1-83]; [@b36-jer-14-1-83]). It is proposed that the discrepancies in the literature may be explained by the degree of plasma glutamine depletion. A marked decrease in plasma glutamine (i.e., values below 400 mmol/L) seems to be the threshold beyond which immune dysfunction occurs ([@b11-jer-14-1-83]). In such cases, glutamine supplementation might be beneficial to the immune system. In contrast, when plasma glutamine is only slightly reduced, which appears to be the case in many studies showing no effect of glutamine supplementation ([@b19-jer-14-1-83], [@b20-jer-14-1-83]; [@b36-jer-14-1-83]), immunosuppression would not be linked to plasma glutamine depletion and, therefore, supplementation would not be beneficial.

Rapid weight loss-induced immunosuppression could be related to severe glutamine depletion, since prolonged fasting has been shown to reduce the *de novo* synthesis of glutamine and increase its degradation via conversion to glucose (i.e., gluconeogenesis \[[@b13-jer-14-1-83]\]). Thus, severe food restriction may deplete circulating glutamine levels ([@b4-jer-14-1-83]). Additionally, intense exercise and increased training loads may reduce plasma glutamine concentrations ([@b16-jer-14-1-83]; [@b27-jer-14-1-83]). Therefore, we sought to examine whether rapid weight loss would deplete plasma glutamine in combat athletes. We also examined whether rapid weight loss would lead to immunosuppression and symptoms of opportunistic infections, and whether glutamine supplementation could ameliorate these responses.

MATERIALS AND METHODS
=====================

Participants
------------

Fifty-eight male combat athletes volunteered to participate in the study. After being assessed for eligibility, 28 athletes were randomised and allocated to receive either glutamine or placebo; 23 athletes completed the study (glutamine: n=12; age, 20±2 years; height, 1.70±0.07 m; body mass, 71.7±7.6 kg; body fat, 9.4%± 2.8% and placebo: n=11; age, 23±5 years; height, 1.71±0.09 m; body mass, 77.4±13.6 kg; body fat, 12.1%±6.1%; [Fig. 1](#f1-jer-14-1-83){ref-type="fig"}). All athletes were competing in official judo (n=20), wrestling (n=1), and taekwondo (n=2) competitions. Inclusion criteria were: (a) 18--30 years of age, (b) minimum training volume of 10 hr/wk, (c) minimum 6 years of experience in the sport, and (d) regularly reduce body weight by 5%--10% before competing. Exclusion criteria were: (a) use of tobacco, (b) use of medications which affect the immune system in the past 2 months, (c) presence of diagnosed infectious disease in the past two months, (d) presence of symptoms suggesting infectious diseases, and (e) use of any nutritional supplement containing glutamine or other substances that may modify immune function. In addition to the 28 athletes who were randomised, eight judo athletes who did not meet a specific inclusion criterion (i.e., not losing weight to compete) were included in the control group in order to control for the effect of competition on the assessed variables (age, 24±6 years; height, 1.74±0.05 m; body mass, 84.4±24.2 kg; body fat, 15.6%±9.8%). The study was approved by the Institutional ethics committee (approval number: 2012/11) and all athletes provided written informed consent prior to participation.

Study design
------------

In this double blind, randomised, placebo-controlled study, athletes were assessed on three separate occasions before a competition: 21 days before (−21d; baseline, a period in which athletes are at their normal body weight), 1 day before (−1d; precompetition, a period in which athletes are close to their competitive weight), and 5 days after a competition (+5d; postcompetition, a period in which normal weight is recovered). Those who had to lose weight were randomly allocated into glutamine or isonitrogenated placebo groups. Athletes in the control group were not randomised as they did not receive any treatment and did not lose weight to compete. On all three occasions, assessments were conducted early in the morning and included body mass, body composition, food intake, and symptoms of infection. Fasting morning-time venous blood samples were also collected for the determination of cortisol, total protein, glutamine, creatine kinase (CK) and selected parameters of immune function. In the control group, however, parameters of immune function were not determined due to a malfunction in the equipment resulting in the loss of seven out of the eight samples.

Supplementation protocol
------------------------

Athletes received glutamine (Ajinomoto Co. Inc., Tokyo, Japan; 21 g/day split into 3 daily doses of 7 g each) or placebo (ovalbumin, Manchester Inc., Sao Paulo, Brazil; 26 g/day split into 3 daily doses of \~8.7 g each). Ovalbumin was chosen due to its relatively high nitrogen and low glutamine content; the dose used contained the same amount of nitrogen with only 1.9 g of glutamine. The supplementation period was 10 days, starting on the 5th day before competition and ending on the 5th day after competition. This supplementation period was chosen because it is well documented that the vast majority of athletes start losing weight in the week of competition, with most weight being reduced in the last 3 days prior to weigh-in ([@b2-jer-14-1-83]). In addition, reports indicate that immunosuppression peaks a few days following rapid weight loss ([@b15-jer-14-1-83]; [@b18-jer-14-1-83]). All supplements were provided in gelatin capsules. At the end of the supplementation period, athletes reported any perceived side effects related to supplementation, returned leftover capsules and attempted to identify which substance they were taking, so that we could confirm blinding efficacy. All methods used for reducing weight were recorded.

Blood sampling
--------------

After collection, 8-hr-fasting venous blood samples were placed on ice and then centrifuged at 2,000 g for 5 min at 4°C. Ethylenediaminetetraacetic acid (EDTA)-plasma was used for the determination of glutamine and CK whereas serum was used for cortisol and total protein determination. Fresh blood samples collected in EDTA-containing tubes were used for the assessment of neutrophil and monocyte phagocytic activity and oxidative burst.

Serum and plasma analysis
-------------------------

Plasma CK and plasma glutamine were determined using enzymatic colorimetric-based kits (BT1100200, Biotecnica, Varginha, Brazil; EnzyChromTM, Bioassay Systems, Hayward, CA, USA). Total protein was assessed using the Bradford reagent (Quick Start, BIO-RAD Laboratories, Hercules, CA, USA). Serum cortisol was determined by an enzyme-linked immunosorbent assay (GWB-CE6F97, Genway, San Diego, CA, USA).

Body composition
----------------

Skinfold thicknesses were measured from 3 sites (triceps, subscapular, and abdominal). Body fat was estimated according to Lohman's equation, which was previously validated for combat athletes ([@b14-jer-14-1-83]).

Dietary assessment
------------------

Food records were used to assed food intake. For the preweight loss period (i.e., −21d), values from the 3 nonconsecutive days were averaged. The remaining food intake records (i.e., −3d, −2d, −1d, +5d) were included individually in the analysis. Total energy and macronutrient intake were calculated with the aid of nutritional assessment software (Dietpro, Viçosa, Brazil).

Upper respiratory infection symptoms
------------------------------------

Occurrence and severity of symptoms of the upper respiratory tract were assessed using the Portuguese version of the Wisconsin upper respiratory symptom survey questionnaire (WURSS).

Neutrophil and monocyte phagocytic activity and oxidative burst
---------------------------------------------------------------

To assess neutrophil and monocyte phagocytic activity, 100 μL of fresh blood was incubated for 35 min at 37°C with 25 μL of zymosan-FITC (5 mg/mL). After incubation, 2 mL of lysis buffer (155 mM NH~4~Cl, 10 mM NaHCO~3~, 0.1 mM EDTA, pH 7.2) was added; samples were then centrifuged and washed with 2-mL phosphate buffered saline - PBS (KH~2~PO~4~ 5 mM, K~2~HPO~4~ 1.2 mM, NaCl 150 mM, pH 7.0). Fluorescence was read on a flow cytometer (FACS CANTO II, BD Biosciences, San Jose, CA, USA) and data were analysed using the FlowJo software (FlowJo, LLC, Ashland, OR, USA) with monocyte and neutrophil populations being identified by size and granularity.

To assess oxidative burst, 100 μL of fresh blood was incubated for 10 min at room temperature with 2 mL of lysis buffer and then 3 mL of PBS-serum (phosphate-buffered saline solution plus 2% bovine serum) was added. Samples were then centrifuged (400 g, 4°C, 5 min) and cells resuspended in 1 mL of PBS-serum. Cells were stimulated with phorbol-12-myristate-13-acetate 100 ng/mL for 20 min at 37°C. After washing with PBS-serum, 1 μL of 2′,7′-dichlorofluorescin diacetate 5 μM was added to detect reactive oxygen species (ROS) production. After a 15-min incubation period, fluorescence was read on a flow cytometer (FACS CANTO II, BD Biosciences, San Jose, CA, USA) and analysed using the FlowJo software (FlowJo, LLC).

Statistical analysis
--------------------

All participants' baseline characteristics (−21d) were compared between groups using a General Linear Model. Mixed model analysis was used to test the effects of weight reduction (time), glutamine supplementation (treatment), and time by treatment interaction on all variables, except the symptoms of infection. Four different structures of covariance were tested to identify the best model for each data set according to the Schwarz's Bayesian criterion. Single-degree-of-freedom contrast analysis was used to test single effects. Kruskal--Wallis tests were conducted to compare the WURSS scores between the three groups at both −1d and +5d followed by the Conover *post hoc* procedure. Frequencies (i.e., number of athletes reporting symptoms of infection and number of methods used to reduce weight) were compared between groups using the Fisher exact test. Data are described as mean ± standard deviation and the level of significance was set at 5%.

RESULTS
=======

No significant differences in participants' characteristics were found between groups at baseline (body mass: *F*=1.86, *P*=0.17; body fat: *F*=2.28; *P*=0.12; age: *F*=1.84; *P*=0.18; height: *F*= 0.74, *P*=0.49). The mean weight reduction, when combining both glutamine and placebo groups, was 5.7±2.3 kg (8.3%± 3.3% of body mass). There were no significant differences between groups for weight reduction (placebo: 6.1±2.4 kg or 8.5%±2.4%; glutamine: 5.2±2.1 kg or 8.2%±4.1%; *P*=0.86; 95% confidence interval \[CI\], −2.67 to 3.18). Mixed models revealed a significant main effect of time for both absolute (*F*=23.2; *P*\<0.0001) and relative (*F*=16.9, *P*\<0.0001) body mass across the study, with no effect of group or group by time interaction being found (*P*\>0.05) ([Fig. 2](#f2-jer-14-1-83){ref-type="fig"}). Five days after competition, glutamine and placebo groups displayed a significant, yet incomplete, recovery of body mass ([Fig. 2](#f2-jer-14-1-83){ref-type="fig"}). In the control group, body mass remained stable (−21d: 86.1±25.9 kg; −1d: 86.8±26.4 kg; +5d: 87.1±25.8 kg; *F*=0.01; *P*=0.99). Athletes in the glutamine and placebo groups used a combination of several weight loss methods (placebo: 2±1 methods; glutamine: 2±1 methods) which were intensified 3--5 days prior to competition and relied on severe energy restriction and dehydration ([Supplementary Table 1](#s1-jer-14-1-83){ref-type="supplementary-material"}).

The majority of athletes (74%, or 17 out of 23) who reduced weight reported symptoms of upper respiratory infection at some point of the study, irrespective of group (glutamine group: 67%, or 8 out of 12; placebo group: 72%, or 8 out of 11, *P*=0.55). In the control group, however, only 2 out of 8 athletes (25%) reported symptoms of infection (control vs. glutamine: *P*=0.08; control vs. placebo: *P*=0.05). The Kruskal--Wallis test revealed significant differences for WURSS scores between groups at −1d (*P*=0.019) but not at +5d (*P*=0.18). At −1d, WURSS scores were not statistically different between glutamine and placebo groups (*P*=0.13), highlighting the lack of effect of glutamine supplementation. On the other hand, both groups tended to report statistically higher scores than the control group (glutamine vs. control, *P*=0.08; placebo vs. control, *P*=0.004), highlighting the impact of rapid weight loss on the incidence of infection symptoms ([Fig. 3](#f3-jer-14-1-83){ref-type="fig"}).

Rapid weight loss led to significant changes in some parameters of immune cell function, but glutamine had no influence on these changes. Oxidative burst in monocytes and neutrophils remained unchanged throughout the study, regardless of supplementation ([Table 1](#t1-jer-14-1-83){ref-type="table"}). In monocytes, we observed a minor fluctuation in phagocytic activity across the study (main effect of time: *F*=5.5, *P*=0.01) ([Table 1](#t1-jer-14-1-83){ref-type="table"}). In neutrophils, the impact of rapid weight loss on phagocytic activity was more pronounced, with increased phagocytosis being observed in both groups at −1d and +5d in comparison to −21d (main effect of time: *F*=7.4, *P*=0.004) ([Table 1](#t1-jer-14-1-83){ref-type="table"}). Glutamine supplementation did not influence phagocytic activity in monocytes (group by time interaction: *F*=0.70, *P*=0.503) or neutrophils (group by time interaction: *F*=1.56, *P*=0.222).

Rapid weight loss did not affect plasma glutamine concentrations (main effect of time: *F*=1.24, *P*=0.27) and glutamine supplementation was not effective in increasing plasma glutamine concentrations (group by time interaction: *F*=1.21, *P*=0.32) ([Table 2](#t2-jer-14-1-83){ref-type="table"}). Serum cortisol was not influenced by weight loss (main effect of time: *F*=1.23, *P*=0.79) or supplementation (group by time interaction: *F*=0.67, *P*=0.11). Conversely, rapid weight loss significantly reduced total serum protein (main effect of time: *F*=6.28, *P*=0.014) and increased plasma CK levels (main effect of time: *F*=3.31, *P*=0.019). Contrast analysis revealed that CK was elevated solely in the placebo group, remaining statistically similar to baseline in the glutamine group ([Table 2](#t2-jer-14-1-83){ref-type="table"}).

Food intake analysis confirmed that athletes severely restricted food intake in the days preceding competition. Glutamine and placebo groups significantly reduced energy and macronutrient intake in comparison to control group, but did not differ between each other ([Table 3](#t3-jer-14-1-83){ref-type="table"}).

Five participants in the placebo group (42%) and five in the glutamine group (45%) were able to correctly identify the supplement they were taking. There was no difference between the correct supplement identification rate and the expected rate of correct identification from a random guess (Fischer exact test: *P*=0.99). Based on the number of returned leftover capsules, adherence to supplementation was 90%±11% and 87%±13% for glutamine and placebo groups, with no differences between groups being found (unpaired *t*-test: *P*=0.41; 95% CI, −14.8 to 6.3). Only two participants in the placebo group reported adverse gastrointestinal effects (stomach acid reflux and flatulence). No adverse effects were reported in the glutamine group.

DISCUSSION
==========

The aggressive methods used by combat athletes to rapidly reduce their body weight include increased training loads and restricted food intake, both potentially capable of depleting circulating glutamine levels ([@b13-jer-14-1-83]; [@b36-jer-14-1-83]), and lead to impaired immune function and increased frequency of infections ([@b15-jer-14-1-83]; [@b18-jer-14-1-83]). Since critically low plasma glutamine has been implicated in immunosuppression ([@b5-jer-14-1-83]; [@b6-jer-14-1-83]), we hypothesized that immunosuppression in athletes undergoing rapid weight loss would be linked to reduced plasma glutamine and that glutamine supplementation could attenuate a potential immunosuppression by replenishing circulating glutamine levels. In our study, as expected, a clear increase in symptoms of infection was observed in both weight loss groups during and following rapid weight loss, but not in the control group. This suggests that athletes experienced some level of immunosuppression that was related to rapid weight loss. Surprisingly, rapid weight loss did not impact monocyte and neutrophil oxidative burst and an increase in neutrophil phagocytic activity was observed. Nevertheless, the increased frequency of infection symptoms was neither associated with plasma glutamine depletion, nor was glutamine supplementation capable of minimising them.

While exercise generally increases the phagocytic activity of neutrophil and monocytes, the negative effect of rapid weight loss on cell-mediated immunity highlights the role of restricted energy intake ([@b18-jer-14-1-83]), increased exercise volume ([@b23-jer-14-1-83]) and chronic hypohydration ([@b33-jer-14-1-83]) on the immunosuppression accompanying rapid weight loss. In our study, we observed no effects of rapid weight loss on the neutrophil and monocyte ability to produce ROS, a fundamental microbicidal effector response. Similarly, we observed a statistically significant fluctuation in monocyte phagocytic activity, although the magnitude was rather small and likely of little physiological relevance. On the other hand, a considerably large increase in neutrophil phagocytic activity was observed, which could be interpreted as a lack of immunosuppressive effects of rapid weight loss; that is in opposition to the current literature. However, the improved neutrophil phagocytic activity could have been a mere reflex of decreased number of circulating neutrophils, a response that has been observed after intensive exercise and caloric restriction ([@b10-jer-14-1-83]; [@b29-jer-14-1-83]). However, we did not measure neutrophil counts in this study. Our results concerning ROS and phagocytosis from circulating monocytes and neutrophils did not support to the notion that rapid weight loss is associated with decreased immunity. However, we did observe an increased frequency and severity of infection symptoms during and after weight reduction. Therefore, it is likely that other aspects of the immune response that we did not evaluate in this study, such as adaptive immune cells as well as humoral immunity and mucosal immunity, all of which have been implicated in rapid-weight-loss-associated immunosuppression ([@b9-jer-14-1-83]; [@b32-jer-14-1-83]), could have played a role in the increased susceptibility to opportunistic infections.

In contrast to our initial hypothesis, rapid weight loss did not lead to glutamine depletion. Thus, other factors unrelated to plasma glutamine concentrations likely contributed to the apparent immunosuppression. One explanation could relate to increased cortisol concentrations, which might affect some aspects of immune function ([@b28-jer-14-1-83]). However, studies have shown either minor increases in cortisol with values within the normal range ([@b8-jer-14-1-83]) or no changes after rapid weight loss ([@b32-jer-14-1-83]). Therefore, the lack of an effect of rapid weight loss on cortisol shown here is in line with the literature and cannot explain the increased frequency of infection symptoms observed in our study. In fact, nutrient availability appears to have only a minor effect on cortisol levels ([@b25-jer-14-1-83]). Alternative explanations for the increased frequency of infection symptoms may relate to (a) intensified training loads, which have been associated with reduced circulating and mucosal levels of immunoglobulins ([@b12-jer-14-1-83]; [@b31-jer-14-1-83]), (b) reduced energy and/or macronutrient intake, which has also been linked to impairments in several aspects of the cellular, systemic and mucosal immune defenses ([@b26-jer-14-1-83]), or (c) a combination of both.

Previous reports have suggested that the lack of positive effects of glutamine supplementation in humans could be explained by the fact that plasma glutamine depletion must be severe to limit immune function. Despite the severe energy restriction and increased training loads in the days preceding competition, none of the athletes showed plasma glutamine levels below 400 mmol/L. Thus, the lack of effect of glutamine supplementation on symptoms of infection can be explained by the remarkably stable plasma glutamine across the study, despite the extreme weight fluctuation and the aggressive methods used to reduce weight. Interestingly, plasma glutamine levels were not elevated in the glutamine group. This, however, is likely explained by the kinetics of appearance and removal of glutamine in blood after oral ingestion ([@b35-jer-14-1-83]). The single doses used in the present investigation (7 g) are similar to that previously shown to elevate plasma glutamine ([@b35-jer-14-1-83]). Since our supplementation protocol required athletes to ingest 7 g every 4--5 hr, it is reasonable to assume that plasma glutamine levels were constantly elevated in the glutamine group ([@b35-jer-14-1-83]).

In the present investigation, plasma CK was increased after rapid weight loss in the placebo group only, with a nonsignificant increase being observed in the glutamine group and no change in the control group. These results were somewhat expected, since previous studies have shown that rapid weight loss induces a significant alteration in CK levels ([@b37-jer-14-1-83]). This suggests that glutamine might play a role in attenuating muscle damage after exhaustive exercise, which is in accordance with previous research ([@b34-jer-14-1-83]). However, all plasma CK values were within the normal range across the study. Therefore, our data does not support any clinical benefit of glutamine in attenuating muscle damage.

The present study is not without its limitations. First, we were unable to access athletes for blood collection on competition day (i.e., when weight loss peaks. Second, we were unable to perform a comprehensive examination of the immune function. Finally, we acknowledge the limitations of self-reported infection symptoms, as they could be related to noninfectious causes, such as allergy and mucosal inflammation. However, it is very unlikely that allergy and non-infectious inflammation could explain the increase in symptoms frequency only in the groups reducing weight but not in controls.

To conclude, the present study confirmed that rapid weight loss leads to increased frequency of symptoms of infection. However, this was not linked to decreased glutamine levels, nor was glutamine supplementation capable of counteracting the apparent decreased immunity during rapid weight loss. Immunosuppression induced by rapid weight loss is not related to circulating glutamine levels; therefore, glutamine supplementation is not beneficial for supporting immune function in combat athletes undergoing rapid weight loss.
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![Absolute (A) and relative (B) weight fluctuation throughout the study. Panel A depicts body mass relative to the individual weight class limit. Iso-N, isonitrogenated placebo; −21d, 21 days before; −1d, 1 day before; +5d, 5 days after. ^a)^Different from −21d (main effect of time). ^b)^Different from −1d (main effect of time). No significant between-group differences were observed.](jer-14-1-83f2){#f2-jer-14-1-83}

![(A) Individual Wisconsin upper respiratory symptom survey (WURSS) scores reported before and after weight loss in the glutamine (Glu), placebo (Pla), and control (Con) groups. (B) Median, interquartile intervals and range for WURSS scores in the glutamine, placebo and control groups 1 day before competition (−1d) and 5 days following competition (+5d) (asterisks denotes outliers). −21d, 21 days before; −1d, 1 day before; +5d, 5 days after. Not significant (ns), *P*\>0.1. ^\#^*P*=0.08 vs. glutamine. ^\$^*P*=0.004 vs. placebo.](jer-14-1-83f3){#f3-jer-14-1-83}

###### 

Oxidative burst and phagocytic activity in monocytes and neutrophils before and after rapid weight loss

  Variable                   Iso-N placebo   Glutamine                                                                                                                                                                                       
  -------------------------- --------------- ----------------------------------------------------------- ----------------------------------------------------------- ------------- --------------------------------------------------------- -----------------------------------------------------------
  Oxidative burst (FI)                                                                                                                                                                                                                       
   Monocyte                  1,418±1,284     1,305±1,763                                                 1,164±708                                                   1,215±1,255   2,381±1,854                                               1,682±725
   Neutrophil                8,016±9,594     7,078±6,383                                                 7,012±5,948                                                 6,770±7,585   7,734±5,021                                               9,029±5,790
                                                                                                                                                                                                                                             
  Phagocytic activity (FI)                                                                                                                                                                                                                   
   Monocyte                  4,421±3,634     3,329±6,283[a)](#tfn3-jer-14-1-83){ref-type="table-fn"}     3,243±2,553                                                 4,051±3,186   3,106±2,625[b)](#tfn4-jer-14-1-83){ref-type="table-fn"}   4,981±4,598[c)](#tfn5-jer-14-1-83){ref-type="table-fn"}
   Neutrophil                5,251±2,986     17,428±22,374[d)](#tfn6-jer-14-1-83){ref-type="table-fn"}   21,125±21,934[e)](#tfn7-jer-14-1-83){ref-type="table-fn"}   6,096±3,549   11,029±17,113                                             28,186±21,032[f)](#tfn8-jer-14-1-83){ref-type="table-fn"}

Values are presented as mean±standard deviation.

Iso-N, isonitrogenated placebo; −21d, 21 days before; −1d, 1 day before; +5d, 5 days after; FI, fluorescence intensity; ES, effect size.

Within-group effect: *P*=0.02 vs. −21d (ES=0.22).

Within-group effect: *P*=0.035 vs. −21d (ES=0.32).

Within-group effect: *P*=0.052 vs. −1d (ES=0.52).

Within-group effect: *P*=0.058 vs. −21d (ES=0.96).

Within-group effect: *P*=0.048 vs. −21d (ES=1.27).

Within-group effect: *P*=0.009 vs. −21d (ES=1.80).

###### 

Effects of rapid weight loss and glutamine supplementation on plasma glutamine, creatine kinase, serum cortisol, and total serum protein

  Group                       Time                                                                
  --------------------------- ----------- ------------------------------------------------------- -----------------------------------------------------
  Plasma glutamine (μmol/L)                                                                       
   Placebo                    791±229     749±230                                                 741±245
   Glutamine                  830±258     835±243                                                 895±354
   Control                    1,075±161   912±298                                                 1,004±392
                                                                                                  
  Total protein (mg/dL)                                                                           
   Placebo                    8.2±1.8     6.9±1.6[a)](#tfn11-jer-14-1-83){ref-type="table-fn"}    7.4±2.0
   Glutamine                  8.3±1.7     7.1±1.6[b)](#tfn12-jer-14-1-83){ref-type="table-fn"}    7.0±1.6
   Control                    7.2±1.5     8.0±1.5                                                 6.9±1.3
                                                                                                  
  Plasma cortisol (ng/mL)                                                                         
   Placebo                    132±72      118±57                                                  103±56
   Glutamine                  151±99      121±71                                                  112±72
   Control                    142±125     141±66                                                  154±75
                                                                                                  
  Creatine kinase (U/L)                                                                           
   Placebo                    125±54      187±73.5[c)](#tfn13-jer-14-1-83){ref-type="table-fn"}   111±59[d)](#tfn14-jer-14-1-83){ref-type="table-fn"}
   Glutamine                  136±58      169±65                                                  130±64
   Control                    123±81      116±45                                                  138±55

Values are presented as mean±standard deviation.

−21d, 21 days before; −1d, 1 day before; +5d, 5 days after.

Within-group effect: *P*=0.0001 vs. −21d (ES=0.76).

Within-group effect: *P*=0.026 vs. −21d (ES=0.73).

Within-group effect: *P*=0.02 vs. −21d (ES=0.92).

Within-group effect: *P*=0.005 vs. −1d (ES=1.07).

###### 

Energy and macronutrient intake in the glutamine and placebo group across the study

  Variable               Placebo   Glutamine   Control                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  ---------------------- --------- ----------- ------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ --------- ------------------------------------------------------ --------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------- --------- --------- ------------------------------------------------------ ------------------------------------------------------ ---------
  Energy (kj/kg)         121±33    138±33      92±38                                                  42±25[a](#tfn17-jer-14-1-83){ref-type="table-fn"},[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}                                                                                               117±29[d)](#tfn20-jer-14-1-83){ref-type="table-fn"}    180±54    92±71[a)](#tfn17-jer-14-1-83){ref-type="table-fn"}     54±58[a)](#tfn17-jer-14-1-83){ref-type="table-fn"}                                                  25±38[a](#tfn17-jer-14-1-83){ref-type="table-fn"},[b](#tfn18-jer-14-1-83){ref-type="table-fn"},[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}      155±59[c](#tfn19-jer-14-1-83){ref-type="table-fn"},[d)](#tfn20-jer-14-1-83){ref-type="table-fn"}    121±46    134±29    159±25                                                 121±38[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}    134±38
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Protein (g/kg)         1.0±0.2   2.7±1.0     2.3±1.7                                                1.6±1.3                                                                                                                                                                                       2.0±1.3                                                1.0±0.4   1.6±1.3                                                1.4±1.9                                                                                             0.5±0.8                                                                                                                                           2.0±1.8[d)](#tfn20-jer-14-1-83){ref-type="table-fn"}                                                1.2±0.2   1.5±0.4   2.0±0.8                                                1.9±0.7                                                2.4±0.9
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Carbohydrates (g/kg)   3.7±1.9   3.9±1.6     2.9±1.5                                                1.1±0.7[a](#tfn17-jer-14-1-83){ref-type="table-fn"},[b](#tfn18-jer-14-1-83){ref-type="table-fn"},[c](#tfn19-jer-14-1-83){ref-type="table-fn"},[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}   3.4±1.0[d)](#tfn20-jer-14-1-83){ref-type="table-fn"}   3.6±1.1   2.9±2.7                                                1.3 ±2.0[a)](#tfn17-jer-14-1-83){ref-type="table-fn"}                                               0.6 ±0.8[a](#tfn17-jer-14-1-83){ref-type="table-fn"},[b](#tfn18-jer-14-1-83){ref-type="table-fn"},[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}   4.4±2.0[c](#tfn19-jer-14-1-83){ref-type="table-fn"},[d)](#tfn20-jer-14-1-83){ref-type="table-fn"}   3.0±0.5   3.2±1.2   3.8±1.4                                                3.6±1.4[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}   3.6±1.2
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Fat (g/kg)             1.1±0.3   0.7±0.3     0.6±0.4[a)](#tfn17-jer-14-1-83){ref-type="table-fn"}   0.2± 0.4[a](#tfn17-jer-14-1-83){ref-type="table-fn"},[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}                                                                                            0.7±0.3[d)](#tfn20-jer-14-1-83){ref-type="table-fn"}   1.2±0.2   0.6±0.5[a)](#tfn17-jer-14-1-83){ref-type="table-fn"}   0.3±0.4[a](#tfn17-jer-14-1-83){ref-type="table-fn"},[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}   0.1±0.1[a](#tfn17-jer-14-1-83){ref-type="table-fn"},[b](#tfn18-jer-14-1-83){ref-type="table-fn"},[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}    0.8±0.4[c](#tfn19-jer-14-1-83){ref-type="table-fn"},[d)](#tfn20-jer-14-1-83){ref-type="table-fn"}   1.3±0.4   1.5±0.3   0.9±0.1[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}   0.8±0.2[e)](#tfn21-jer-14-1-83){ref-type="table-fn"}   0.9±0.2

Values are presented as mean±standard deviation.

−21d, 21 days before; −3d, 3 days before; −2d, 2 days before; −1d, 1 day before; +5d, 5 days after.

Within-group effect vs. −21d.

Within-group effect vs. −3d.

Within-group effect vs. −2 d.

Within-group effect vs. −1d.

Between group effect (control vs. glutamine and control vs. placebo).
